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Abstract 
Unlike Ca2+-dependent normal vascular contraction, the Rho-kinase-mediated 
Ca2+-independent abnormal vascular contraction mediates cerebral and coronary 
vasospasm. As an upstream key molecule of such abnormal Ca2+-independent 
vasocontraction, we identified sphingosylphosphorylcholine (SPC) and Fyn tyrosine 
kinase. The ideal therapeutic agent for vasospasm is to specifically inhibit 
Ca2+-independent contraction without affecting Ca2+-dependent one. We previously 
found the ideal drug eicosapentaenoic acid (EPA) and indeed EPA clinically 
suppressed human vasospasm after subarachnoid hemorrhage. However, lipophilic 
water-soluble compound with the same effects as EPA. 
We screened plant-derived compounds and focused on flavonoids, acacetin and 
its structural isomer biochanin A which is only different in the position of phenyl 
group in chemical structure. Acacetin slightly inhibited 40 mM K+-induced 
Ca2+-dependent contraction in porcine coronary vascular smooth muscle (VSM) strips, 
but inhibited the SPC-induced Ca2+-independent contraction fast and strongly. In 
contrast, biochanin A inhibited 40 mM K+-induced contraction more strongly than the 
SPC-induced contraction. Pre-incubation of acacetin and biochanin A showed 
inhibitory effect on SPC and 40 mM K+-induced contractions indicating that they had 
a superior preventive effect on vascular contractions. The morphological changes 
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induced by SPC in human coronary smooth muscle cells were also inhibited by 
acacetin and biochanin A. Both acacetin and biochanin A strongly inhibited 
SPC-induced Rho-kinase activation and myosin light chain phosphorylation.  
In summary, the difference in the position of the phenyl group on acacetin and 
biochanin A is involved in the inhibitory effect on SPC-induced abnormal contraction. 
Key words: acacetin, biochanin A, SPC, vascular smooth muscle, Rho-kinase  
Introduction
The number of deaths due to the fatal vascular diseases such as angina, 
myocardial infarction and cerebral infarction is almost the second leading cause of 
death following cancer. The pathophysiological reason of these diseases is not the 
abnormality of the heart or brain, but the abnormal contraction of blood vessel 
perfusing these organs. We previously discovered that Rho-kinase plays a pivotal role 
in the Ca2+-sensitization of smooth muscle contraction, as associated with 
Ca2+-independent myosin light chain phosphorylation1). While Ca2+-dependent 
contraction plays a major role in the regulation of physiological blood pressure and 
circulation, Rho-kinase-mediated Ca2+-independent abnormal contraction causes 
cerebral vasospasm after subarachnoid hemorrhage and vasospastic angina. We also 
found sphingosylphosphorylcholine (SPC) is the novel messenger for 
Rho-kinase-mediated Ca2+-sensitization of arterial smooth muscle2). The ideal 
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therapeutic agent for vasospasm is to specifically inhibit Ca2+-independent abnormal 
contraction with little effects on the Ca2+-dependent contraction regulating the normal 
blood pressure and circulation. We previously found that eicosapentaenoic acid (EPA), 
an n-3 polyunsaturated fatty acid, specifically inhibited the SPC-induced abnormal 
contraction without affecting the 40 mM K+-induced contraction in the porcine 
coronary artery3), which satisfied our purpose of treating vasospasm. However, EPA 
has at least two disadvantages, 1) supply instability and 2) limited administration 
method. The problem of supply instability is that most of EPA production depends on 
the purification from fish oil, while overfishing, marine pollution and climate change 
may influence the quality of fish. The problem with the administration method is that 
EPA can be administered only orally because of its lipophilicity, therefore it cannot be 
administered intravenously and thereby it is impossible to save unconscious patients. 
To solve these problems, it is necessary to find the new water-soluble compound as a 
therapeutic agent for vasospasm derived from plants which has a stable supply. 
Flavonoids are a type of polyphenol and a general term for plant pigments of a 
group of naturally organic compounds. Many of them have physiological functions 
for the human and widely distributed in plants. According to the studies in recent 
years, it has been proved that flavonoids have excellent protective effects against 
cancer, cardiovascular diseases and osteoporosis4). However, studies of flavonoids on 
the SPC-induced abnormal vascular contraction has not been clarified yet. In this 
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study, we focused on the structural isomers acacetin and biochanin A of flavonoids. 
Acacetin is found in various plants, such as black locust, damiana, birch and safflower 
species5). Biochanin A is found in red clover, soybeans, peanuts, chickpeas, and other 
legumes6). We found that acacetin and biochanin A inhibited Ca2+-independent 
abnormal contraction of VSM caused by SPC and Ca2+-dependent contraction caused 
by high potassium depolarization in varying degrees and the difference in the position 
of the phenyl group on acacetin and biochanin A may be involved in the inhibitory 
effect on the SPC-induced abnormal contraction. 
Purpose 
In this study, we aimed to find the new plant-derived compounds which were 
water-soluble and were readily available as a therapeutic agent for vasospasm patients. 
We tried to explore the effects of acacetin and biochanin A, which are only different in 
the position of phenyl ring in their chemical structures, on the SPC- and 40 mM 
K+-induced contractions. 
Methods 
1. Materials and reagents 
Sigma-Aldrich (USA). The compounds were dissolved in 100% DMSO to make a 40 
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mM stock solution to store at -20°C and diluted to final concentration before use. SPC 
was purchased from Enzo Life Sciences Inc (USA), Bradykinin (BK) was obtained 
from Peptide Research Institute (Osaka, Japan). All the other reagents were purchased 
from Katayama and Wako (Japan). 
2. Methods 
1) Tissue preparation  
All the procedures were approved by the Institutional Animal Care and Use 
Committee of Yamaguchi University and were conducted in conformity with 
institutional guidelines. Porcine left anterior descending coronary arteries were 
obtained from a local public abattoir (Kitakyushu Municipal Meat Inspection and 
Control Center, Japan). Tissue specimens were placed into ice-cold Krebs solution 
(123 mM NaCl, 4.7 mM KCl, 15.5 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgCl2, 
1.25 mM CaCl2, 11.5 mM D-glucose) and transported to the laboratory. All solutions 
were treated with a mixture of 5% CO2 and 95% O2 (pH adjusted to 7.4 at 4°C). The 
fat tissue and adventitia were removed from the arteries with scissors, and the tunica 
intima was gently scraped off with swabs and the arterial rings were cut into strips 
(0.7 mm × 4 mm). The complete removal of the endothelium from strips was 
confirmed by the lack of relaxation response to 1 µM BK.
2) Measurement of the isometric tension in porcine coronary vascular smooth muscle 
(VSM) strips 
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Tension measurement was performed in the same way as described in the 
previous paper7-10). Smooth muscle strips were placed perpendicularly into the 
8-chamber organ bath LE01086 (Panlab Harvard device, Spain) filled with Krebs 
solution. The solution was gassed with a mixed gas (5% CO2 and 95% O2) and 
maintained at 37°C during the whole experiment. The force converter TB-612T 
(Nippon Photoelectric) was used to measure the isometric force. With adjusting the 
resting tension, 118 mM K+ (10.9 mM NaCl, 116.8 mM KCl, 15.5 mM NaHCO3, 1.2 
mM KH2PO4, 1.2 mM MgCl2, 1.25 mM CaCl2, and 11.5 mM D-glucose) and Krebs 
solutions were alternately applied until 118 mM K+ induced the maximum tension. 
Effects of the compounds on the force were examined at the steady state of the 
pre-contraction induced by 30 µM SPC or 40 mM K+ (88.9 mM NaCl, 38.8 mM KCl, 
15.5 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgCl2, 1.25 mM CaCl2, and 11.5 mM 
D-glucose). The inhibitory extent of contraction induced by the drugs was described 
as a percentage of the response compared to the contractions induced by 30 µM SPC 
or 40 mM K+. The pretreatment-induced contractions were normalized by the ratio 
compared with 118 mM K+ depolarization-induced contraction. 
3) Time-lapse recording of human coronary smooth muscle cells (HCASMCs) 
contraction  
HCASMCs (Kurabo, Osaka, Japan) were cultured in HuMedia-SG2 (Kurabo, 
Osaka, Japan) containing 5% fetal bovine serum (FBS), 0.5 ng/ml human epidermal 
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growth factor (hEGF), 2 ng/mL human fibroblasts growth factor-B (hFGF-B), 5 
µg/mL insulin, 50 µg/mL gentamycin and 50 ng/mL amphotericin B. HCASMCs were 
used for experiments within 3-9 passages after the initiation of culture. When the cell 
confluence reached 80-90%, FBS and growth factor-free HuMedia-SB2 (Kurabo, 
Osaka, Japan) medium was changed to obtain the contractile phenotype of HCASMCs. 
After treatment with HuMedia-SB2 for 24 h, cells were pretreated with or without 40 
µM acacetin and biochanin A for 30 min at 37°C in the incubator. Then, 30 µM SPC 
was added to the medium and time-lapse recording of HCASMCs contraction was 
performed with the phase-contrast microscope (KEYENCE BZ9000, Osaka, Japan) in 
every 32 seconds for 10 minutes and 40 seconds. 
4) Western blot 
Porcine coronary arterial pieces were divided into six groups: (1) no pretreated, 
without SPC stimulation, (2) biochanin A-pretreated (40 µM, 30 min), without SPC 
stimulation, (3) acacetin-pretreated (40 µM, 30 min), without SPC stimulation, (4) no 
pretreated, with SPC stimulation (30 µM, 15 min), (5) biochanin A-pretreated (40 µM, 
30 min), with SPC stimulation (30 µM, 15 min), (6) acacetin-pretreated (40 µM, 30 
min), with SPC stimulation (30 µM, 15 min), and each group was treated according to 
the experimental group. Those arterial pieces were then quickly immersed in 5% 
trichloroacetic acid (TCA) for 10 min and washed twice with chilled 10 mM 
DL-dithiothreitol (DTT)/acetone to remove TCA. Liquid nitrogen was used to freeze 
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the samples, and SK-Mill Freeze-Crush Apparatus (Diagnocine, USA) was used to 
smash the sample to powder in tubes in liquid nitrogen. RIPA buffer (Wako, Japan) 
was added to lysis the tissue samples. The tissue lysates were centrifuged at 12,000 
rpm/min at 4°C and the supernatants were collected and subjected to western blot. 30 
µg protein was loaded and separated by 10% SDS-PAGE and subjected to 
immunoblotting with appropriate antibodies against myosin phosphatase target 
subunit 1 (MYPT1) (Santa Cruz, USA), phospho-Thr853 of MYPT1 (Santa Cruz, 
USA), myosin light-chain (MLC) (Santa Cruz, USA), phospho-Ser19 MLC (Cell 
signaling, USA). All the primary antibodies were diluted 1: 1,000 with 5% skim milk 
in Tris-buffered saline-0.05% Tween-20 (TBS-T). The secondary antibodies were 
diluted 1:5,000 with TBS-T. The signal was visualized using the Super Signal West 
Pico (Thermo Fisher, USA) chemical luminescent substrate and evaluated using 
software named Quantity One with ChemiDoc XRS-J (Bio-Rad, USA).  
3. Statistics  
The data were analyzed with Excel and expressed as mean ± SEM, and n 
represented the number of the assays. -test was used to determine the 
statistical significance between the two groups. Tukey-Kramer was used to analyze 
multiple groups. P-values < 0.05 was defined to be statistically significant. 
Results 
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1. Effects of acacetin and biochanin A on the SPC-induced Ca2+-independent 
abnormal contraction and 40 mM K+-induced Ca2+-dependent contraction 
The structural formulas of acacetin and biochanin A are shown in Figure 1A and 
1B. Acacetin belongs to flavone (Figure 1C) and biochanin A is the structural isomer 
of acacetin belonging to isoflavone (Figure 1D). The only difference between the two 
compounds is the position of the phenyl ring. The effect of this small structural 
difference on the effect of VSM contraction is significantly different. The traces in 
Figure 2A - D showed the typical inhibitory effects of 40 µM acacetin and 40 µM
biochanin A on SPC or 40 mM K+-induced contractions. 20 - 80 µM acacetin and 
biochanin A inhibited SPC and 40 mM K+-induced contractions in a dose-dependent 
manner (Figure 2E, F). 40 - 80 µM acacetin inhibited the SPC-induced contraction 
significantly stronger than 40 mM K+-induced contraction. But 20 µM biochanin A 
significantly inhibited 40 mM K+-induced contraction stronger than the SPC-induced 
contraction, and 40 - 80 µM biochanin A inhibited SPC and 40 mM K+-induced 
contractions to the same extent (Figure 2E, F). Therefore, acacetin was shown to 
specifically inhibit the SPC-induced abnormal vascular contraction in 
post-administration experiments. 
2. Effects of pre-incubating acacetin and biochanin A on SPC and 40 mM 
K+-induced contractions of VSM  
Due to the aim of studying on the preventive effect of acacetin and biochanin A 
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on the VSM contraction, we also investigated the effects of pretreatment of acacetin 
and biochanin A on SPC and 40 mM K+-induced contractions in porcine artery VSM 
strips. Figure 3 showed that pretreatment with acacetin or biochanin A significantly 
inhibited both the SPC and 40 mM K+-induced contractions. After pretreating with 
acacetin, SPC stimulation caused a smaller contraction compared to pretreating with 
biochanin A, which was consistent with the effects of post-administration. Both 
pretreatment with acacetin and biochanin A inhibited the 40 mM K+-induced 
contraction which was different from the effects of post-administration. 
3. Effects of acacetin and biochanin A on the SPC-stimulated morphological 
changes of HCASMCs 
The inhibitory effects of acacetin and biochanin A on the SPC-induced abnormal 
contraction were clarified in porcine coronary arterial strips (tissues), and the effects 
could also be confirmed in HCASMCs. In the SPC group, the morphology of 
HCASMCs changed from spindle shape to round in a time-dependent manner, while 
the cell-free areas expanded at the same time. After the pre-incubation of acacetin and 
biochanin A, HCASMCs had a delayed rate of morphological changes to SPC 
stimulation compared with the SPC group. Therefore, the inhibitory effects of 
acacetin and biochanin A on the SPC-induced contraction were observed not only in 
the porcine coronary artery tissue (Figure 2, 3), but also in human cells (Figure 4). 
These findings suggest that the inhibitory effects of acacetin and biochanin A on the 
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SPC-induced contraction are preserved between species.  
4. Effects of acacetin and biochanin A on the SPC-induced Rho-kinase activation 
and MLC phosphorylation  
Previous studies showed that SPC activated Rho-kinase, then Rho-kinase 
phosphorylated MYPT1 which is a regulatory subunit 1 of myosin-light chain 
phosphatase, and enhanced Ca2+ sensitization to induce the contraction of VSM2, 11-13). 
In this study, we performed western blot experiments on the phosphorylation of 
MYPT1 (phospho-thr-853) to read out the Rho-kinase activity. It was evaluated 
whether the SPC-induced Rho-kinase activation was inhibited by acacetin and 
biochanin A or not14, 15). 30 µM SPC significantly increased the phosphorylation level 
on Thr-853 of MYPT1. But the phosphorylation of MYPT1 on Thr-853 was 
significantly inhibited by both acacetin and biochanin A pretreatment (30 minutes), 
and the inhibitory degree was more obvious in acacetin group. The phosphorylation of 
myosin light chain (MLC) on Ser-19 was measured at the same time (Figure 5). As 
expected, both acacetin and biochanin A inhibited the SPC-induced phosphorylation at 
the site Ser-19 of MLC in the same way as they inhibited phosphorylation of MYPT1 
(Figure 5). These results were also consistent with the results of post- and 
pre-administration experiments (Figure 2 and 3). 
Discussion 
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In the treatment of vasospasm, the vasodilator Ca2+ channel antagonist is 
contraindicated because it may cause hypotension and exacerbate the condition of the 
patients. Therefore, acacetin, which selectively inhibited the SPC-induced contraction, 
is recommended as a candidate for the treatment of vasospasm rather than biochanin 
A, which inhibited 40 mM K+-induced contraction more effectively. 
Hypertension has been shown as a risk factor for subarachnoid cerebral 
aneurysm rupture, and the Stroke Treatment Guidelines 2015 clearly stated that the 
improvement of hypertension was strongly recommended for the patients. The most 
recommended drug for hypertension is Ca2+ channel antagonists, which have the 
effect of inhibiting the 40 mM K+-induced Ca2+-dependent contraction. In 
pretreatment experiments, 40 µM acacetin and 40 µM biochanin A were pretreated 
with the VSM strips for 30 min. Both of them significantly inhibited 40 mM K+ and 
the SPC-induced contractions compared to the control group (Figure 3). These 
findings suggest both acacetin and biochanin A have the capability to inhibit the 
hypertension in the case of prophylactic administration for vasospasm after 
subarachnoid hemorrhage. In hypertensive patients, it may be possible to prevent 
subarachnoid hemorrhage itself. Similar to the results of post-administration in Figure 
2, acacetin had a higher inhibitory ratio on the SPC-induced contraction than 40 mM 
K+-induced contraction, and biochanin A had the opposite effect. 
Acacetin is known to have anti-inflammatory, cardioprotective, and antitumor 
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effects5). AMPK activation is known to be one of the mechanisms of acacetin16, 17). In 
recent years, plant-derived natural compound madagascine has been reported to 
suppress the SPC/Rho-kinase pathway through AMPK activation18, 19). Therefore, 
acacetin may also inhibit the SPC/Rho-kinase pathway through AMPK activation. 
Biochanin A is also known to have anti-inflammatory, antitumor, and estrogen effects, 
but as far as we know, biochanin A has not been reported to activate AMPK or Rho- 
kinase.  
Nakao et al. of our lab suggested that the SPC-induced Ca2+-sensitization in 
porcine coronary artery was mediated specifically by Src family tyrosine kinase 
(Src-TK) and showed that SPC induced the translocation of Fyn, a member of Src-TK, 
from cytosol to cell membrane. But the translocation of Rho-kinase and Fyn from the 
cytosol to the cell membrane induced by SPC were inhibited by EPA and PP1 (an 
SrcPTKs inhibitor)3). As acacetin had the similar effect with EPA which selectively 
inhibited the SPC-induced Ca2+-sensitization of VSM contraction with little effect on 
Ca2+-dependent contraction, we doubted that acacetin might also inhibit the 
translocation of Rho-kinase and Fyn from the cytosol to the cell membrane induced 
by SPC, which in turn affected the activity of Rho-kinase. But the further experiments 
should be done to prove it.  
Conclusion 
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Acacetin selectively inhibited the SPC-induced Rho-kinase-mediated 
Ca2+-independent vascular abnormal contraction compared to biochanin A. The 
position of the phenyl group in the structural isomers acacetin and biochanin A might 
explain the different effects of acacetin and biochanin A on the SPC-induced 
Ca2+-independent abnormal VSM contraction and the inhibition of Rho-kinase 
activation.  
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Figure 1 
Figure 1 The chemical structures of acacetin, biochanin A, flavone, and isoflavone. (A) The 
chemical structure of acacetin. (B) The chemical structure of biochanin A. (C) The chemical structure 
of flavone. (D) The chemical structure of isoflavone. 
Figure 2 
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Figure 2 Inhibitory effects of acacetin and biochanin A on the SPC-induced abnormal contraction 
-induced Ca2+-dependent contraction in porcine coronary vascular smooth muscle 
strips (A-D) The effects of acacetin and biochanin A (40 µM) on the SPC-induced (30 µM) abnormal 
contraction or -induced contraction in vascular smooth muscle strips. (E, F) Acacetin and 
biochanin A inhibited the SPC-induced Ca2+-independent ab -induced 
Ca2+-dependent contraction in dose-response manner in vascular smooth muscle strips. Data were 
expressed as mean ± SEM (n = 3). The inhibitory ratio was calculated as comparing the tension before 
adding the compounds with the tension 1 hour after adding the compounds. * P < 0.05, SPC: 
sphingosylphosphorylcholine, BK: bradykinin
Figure 3 
Figure 3 The pre-incubation effects of acacetin and biochanin A on SPC and 40 mM K+-induced 
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contractions in porcine coronary arterial strips. The VSM strips were pretreated with acacetin or 
biochanin A (40 µM) for 30 min at 37°C in Krebs solution, SPC or 40 mM K+ solutions with 
compounds were added to stimulate the contractions. The pre-incubation-induced contractions were 
normalized by the ratio compared with 118 mM K+ depolarization-induced contraction. The statistical 
evaluation showed pre-incubating acacetin and biochanin A with VSM tissue inhibited the SPC and 40 
mM K+-induced contractions significantly. Data were expressed as mean ± SEM. (n = 3, *P < 0.05).  
Figure 4 
Figure 4 Acacetin and biochanin A inhibited the SPC-induced abnormal contraction in human 
coronary smooth muscle cells (HCASMC). HCASMCs were serum starved for 24 hours before the 
experiment. Pre-incubating the cells with or without acacetin and biochanin A for 30 min, and then 
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stimulated with SPC (30 µM). The time-lapse observation with phase-contrast microscope showed the 
morphological changes in cells of the control group, acacetin group, and biochanin A group. Scale bar: 
100 µm.
Figure 5 
Figure 5 Acacetin and biochanin A inhibited the SPC-induced Rho-kinase activation and 
MLC phosphorylation in vascular smooth muscle strips. (A). After pre-incubating with 
acacetin or biochanin A (40 µM, 30 min) in vascular smooth muscle strips in the presence or 
absence of SPC (30 µM, 15 min), western blot using anti-p-MYPT1 (Thr853), anti-MYPT1, 
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anti-p-MLC (Ser19), anti-MLC antibodies were showed. (B,C) Statistical analysis of Rho-kinase 
activation (proportion of MYPT1 phosphorylation on Thr853 to total MYPT1) and MLC 
phosphorylation (proportion of MLC phosphorylation on Ser19 to total MLC). Data are expressed 
as mean ± SEM (n = 3). * P <0.05. p-MLC: Phosphorylation of myosin light chain, p-MYPT1: 
Phosphorylation of myosin phosphatase regulatory subunit 1. 
